Diagnostic performance of the EU TI‐RADS and ACR TI‐RADS scoring systems in predicting thyroid malignancy
Endocrinology, Diabetes & Metabolism · 2023-07 · 6 (4)
DOI: 10.1002/edm2.434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 16.06.2023. Verfasst von Hiba-Allah Chatti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, La Rabta university hospital, Faculty of medicine, University of Tunis-El Manar, Tunis, Tunisia. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Several ultrasound scoring systems have been developed to stratify the risk of malignancy of thyroid nodules, including ACR (American College of Radiology) and EU (European) TI‐RADS. This study aimed to assess the diagnostic performance of these two classifications using histology as a reference standard.
Methods
It was a single‐centre, retrospective study including 156 patients who underwent thyroidectomy. Ultrasound data of 198 nodules (99 malignant nodules and 99 benign nodules) were analysed. Both classifications were applied for all nodules.
Results
Ultrasound criteria associated with malignancy were solid composition (OR=7.81; p < 10 −3 ), hypoechoic character (OR=16.42; p < 10 −3 ), irregular contours (OR=7.47; p < 10 −3 ), taller‐than‐wide shape (OR=3.58; p = 0.02), microcalcifications (OR=3.02; p = .006) and the presence of cervical adenopathy (OR=3.89; p = .006). The prevalence of malignancy was 15.5%, 69% and 76.9% for EU TI‐RADS categories 3, 4 and 5, respectively. It was 33.3%, 57% and 91.1% for ACR TI‐RADS categories 3, 4 and 5, respectively. For category 5, EU TI‐RADS and ACR TI‐RADS had sensitivities of 60% and 41%, specificities of 82% and 96%, respectively. For categories 4 and 5 combined, the diagnostic performance of these two classification systems became comparable with a sensitivity of 89% and 86% for EU‐TIRADS and ACR‐TIRADS, respectively. The area under the ROC curve was 0.81 for the EU TI‐RADS classification and 0.82 for the ACR TI‐RADS classification.
Conclusions
EU TI‐RADS and ACR TI‐RADS scoring systems seem to be comparable in predicting malignancy in thyroid nodules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, La Rabta university hospital, Faculty of medicine, University of Tunis-El Manar, Tunis, Tunisia.
- Department of Oto-Rhino-laryngology, La Rabta university Hospital, Faculty of medicine, University of Tunis-El Manar, Tunis, Tunisia.
- Department of Radiology, La Rabta university hospital, Faculty of medicine, University of Tunis-El Manar, Tunis, Tunisia.
- Department of Pathology, La Rabta university hospital, Faculty of medicine, University of Tunis-El Manar, Tunis, Tunisia.
ORCID-Profile: Ibtissem Oueslati, Meriem Yazidi
Zitieren
APA
Chatti, H. A., Oueslati, I., Azaiez, A., Marrakchi, J., Boukriba, S., Mizouni, H., Haouet, S., Besbes, G., Yazidi, M., & Chihaoui, M. (2023). Diagnostic performance of the EU TI‐RADS and ACR TI‐RADS scoring systems in predicting thyroid malignancy. Endocrinology, Diabetes & Metabolism, 6(4). https://doi.org/10.1002/edm2.434
Vancouver
Chatti HA, Oueslati I, Azaiez A, Marrakchi J, Boukriba S, Mizouni H, et al. Diagnostic performance of the EU TI‐RADS and ACR TI‐RADS scoring systems in predicting thyroid malignancy. Endocrinology, Diabetes & Metabolism. 2023;6(4). doi:10.1002/edm2.434
BibTeX
@article{Chatti2023,
author = {Chatti, Hiba-Allah and Oueslati, Ibtissem and Azaiez, Aymen and Marrakchi, Jihen and Boukriba, Seif and Mizouni, Habiba and Haouet, Slim and Besbes, Ghazi and Yazidi, Meriem and Chihaoui, Melika},
title = {Diagnostic performance of the EU TI‐RADS and ACR TI‐RADS scoring systems in predicting thyroid malignancy},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2023},
volume = {6},
number = {4},
doi = {10.1002/edm2.434}
}
EUVIMED